Coldstream Capital Management Inc. Has $761,000 Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Coldstream Capital Management Inc. lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 56.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,410 shares of the medical equipment provider’s stock after buying an additional 3,388 shares during the period. Coldstream Capital Management Inc.’s holdings in Hologic were worth $761,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HOLX. Innealta Capital LLC acquired a new position in Hologic in the 2nd quarter worth about $25,000. Wolff Wiese Magana LLC acquired a new position in shares of Hologic in the third quarter valued at approximately $25,000. Groupama Asset Managment raised its holdings in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.6 %

HOLX opened at $75.09 on Friday. The company has a market cap of $17.04 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 2.37 and a beta of 0.96. The company has a fifty day moving average price of $79.45 and a two-hundred day moving average price of $78.56. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1-year low of $69.36 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the business earned $0.89 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HOLX shares. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Jefferies Financial Group assumed coverage on Hologic in a report on Tuesday. They set a “hold” rating and a $85.00 target price on the stock. UBS Group raised their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Raymond James lifted their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research report on Tuesday. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.75% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.